If trial results are positive, Eli Lilly could submit for FDA approval as early as 2025-2026, with potential commercial availability following approval
You are at risk for developing plantar fasciitis if you: Are over age 40 Are female Have flat feet or high arches Are overweight Have an atypical walk pattern, such as inward pronation Engage in activities that place stress on the heel and attached tissue of the foot, such as long-distance running Work in an occupation that requires you to stand or walk on hard or uneven surfaces for a long period Wear shoes with inadequate arch or heel support, or high heels Untreated plantar fasciitis may result in knee, hip, and back pain as you adjust your walking gait to avoid discomfort in your feet
Substances under S0 are classified as non-Specified Substances under the WADA Code
Caution is advised in patients with a history of pancreatitis, severe gastrointestinal disease, diabetic retinopathy, and severe renal impairment
Underlying conditions: digestive disorders like Crohn's or celiac disease, or autoimmune conditions, can cause you to use up B12 faster and may call for more frequent injections
